first_img Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Enter Your Email Address Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! The Synairgen (LSE: SNG) share price surged higher on Friday morning and is up by 28% as I write. The stock rose after positive results from the trial of a drug used to treat coronavirus patients were published in The Lancet Respiratory Medicine journal.The trial results showed that coronavirus patients who received Synairgen’s SNG001 “inhaled formulation of interferon beta-1a” had “greater odds of improvement and recovered more quickly”.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…This news isn’t a complete surprise. Synairgen’s share price rose by over 400% in one day in July when the company originally disclosed the results of this trial.But the publication of the results in a respected, peer-reviewed journal provides an extra layer of credibility. I believe it could pave the way for the larger-scale phase-three trial that would be needed to gain commercial approval.After the vaccine – Is it too late?The stock market has surged this week on hopes that a Covid-19 vaccine produced by US pharma giant Pfizer could help bring the coronavirus pandemic to an end. But I think the reality is that even in a best-case scenario, rolling out the vaccine will take time and it will never be 100% effective.In the meantime, people will continue to catch coronavirus and need treatment. The latest UK government data show that there are currently more than 14,000 Covid patients in UK hospitals. Many other countries have similar numbers.Synairgen’s share price slumped on Monday when the vaccine news emerged. But I think it’s too soon to forget about the need for other treatments. I think there’s a good chance that SNG001 could still find a sizeable commercial market.What happens next?The SNG001 trial that’s being reported on today was a phase-two trial. This means it was relatively small, with just 101 patients. Drug development is a three-stage process. For SNG001 to progress towards commercial approval, a larger phase-three trial will be required.I don’t know how long that might take to complete. But I think it’s worth looking at the broader picture. Before coronavirus took hold at the start of this year, Synairgen was trialling SNG001 for use with patients suffering from COPD, a chronic lung disease.My understanding is that this has been put on the backburner so the firm can focus on Covid-19. But I think it’s fair to say that the work being done now could end up being useful for a broader range of respiratory conditions.In other words, I don’t think Synairgen’s commercial potential is limited to treating Covid.Synairgen share price is up 2,000% in 2020Back in January, Synairgen was trading at just 6p. As I write, the stock is trading at 128p.That’s a gain of more than 2,000% in less than a year.Am I too late to buy the shares? I think it’s hard to say. Synairgen doesn’t currently have any revenue and is loss-making. But if a large-scale trial of SNG001 is successful, I’d guess that regulatory approval could follow quite quickly.I think Synairgen’s share price could go either way from here. Although I can see the potential for further gains, this kind of situation is beyond my personal risk tolerance. For this reason, I won’t be investing. Our 6 ‘Best Buys Now’ Shares Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Roland Head | Friday, 13th November, 2020 | More on: SNG Simply click below to discover how you can take advantage of this.center_img See all posts by Roland Head I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. The Synairgen share price is flying! Here’s what I’d do now Image source: Getty Images I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. “This Stock Could Be Like Buying Amazon in 1997”last_img

 Tags: , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *